M&A / Deals Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia PharmaphorumEli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped.M&A / DealsOncologyRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaphorum Eli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped. M&A / DealsOncologyRead full story Post navigation Previous: The Omnichannel Gap: Building the CRM of the Future for Patient ServicesNext: UK Knowledge Quarter welcomes Boehringer Ingelheim AI accelerator Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
